Skip to content

Post-COVID-19 Chronic Fatigue Syndrome

Post-COVID-19 Chronic Fatigue Syndrome

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05642923
Enrollment
528
Registered
2022-12-08
Start date
2023-01-08
Completion date
2025-03-05
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-COVID-19 Syndrome, Post-COVID Syndrome

Brief summary

Fatigue is recognized as one of the most commonly presented long-term complaints in individuals previously infected with SARS-CoV-2.

Detailed description

It has become increasingly clear that infected patients have symptoms not only in the acute phase, but also after recovery from the initial infection. A recent meta-analysis including 4828 patients with post-COVID-19 showed that symptoms and post-acute sequelae of SARS-CoV-2 can persist weeks to months after the infection. These patients who reported persistent symptoms have been termed long haulers or described as having long COVID, post-acute COVID-19, persistent COVID-19 symptoms, post COVID-19 manifestations, long-term COVID-19 effects, post-acute sequelae of COVID-19 (PASC), or post-COVID-19 syndrome.

Interventions

DRUGSynthetic Vitamin B1

Synthetic Vitamin B1 400 mg per day

Sponsors

As-Salam Center, Maadi, Cairo, Egypt
CollaboratorUNKNOWN
ClinAmygate
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age . 18 * Male or female * Post-Covid-19 Fatigue

Exclusion criteria

* refusal

Design outcomes

Primary

MeasureTime frameDescription
Fatigue scaleone monthchalder fatigue scale: the minimum = 0 and maximum values = 33, and whether higher scores mean a worse outcome.

Secondary

MeasureTime frameDescription
Incidence of adverse events6 monthsIncidence of adverse events

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026